AMG-9810

Chemical compound
AMG-9810
Identifiers
  • (E)-3-(4-tert-butylphenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)prop-2-enamide
CAS Number
  • 545395-94-6
PubChem CID
  • 680502
ChemSpider
  • 592741
UNII
  • 182HIJ2D7F
ChEBI
  • CHEBI:92757
ChEMBL
  • ChEMBL195789
CompTox Dashboard (EPA)
  • DTXSID40202960 Edit this at Wikidata
ECHA InfoCard100.164.996 Edit this at Wikidata
Chemical and physical data
FormulaC21H23NO3
Molar mass337.419 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC(C)(C)C1=CC=C(C=C1)/C=C/C(=O)NC2=CC3=C(C=C2)OCCO3
InChI
  • InChI=1S/C21H23NO3/c1-21(2,3)16-7-4-15(5-8-16)6-11-20(23)22-17-9-10-18-19(14-17)25-13-12-24-18/h4-11,14H,12-13H2,1-3H3,(H,22,23)/b11-6+
  • Key:GZTFUVZVLYUPRG-IZZDOVSWSA-N

AMG-9810 is a drug which acts as a potent and selective antagonist for the TRPV1 receptor.[1] It has analgesic and antiinflammatory effects and is used in scientific research, but has not been developed for medical use. It has high antagonist potency and good bioavailability and pharmacokinetics, and so has been used to study the role of TRPV1 in areas other than pain perception, such as its roles in the brain.[2][3][4][5][6]

See also

  • AMG-517
  • SB-705498

References

  1. ^ Doherty EM, Fotsch C, Bo Y, Chakrabarti PP, Chen N, Gavva N, et al. (January 2005). "Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides". Journal of Medicinal Chemistry. 48 (1): 71–90. doi:10.1021/jm049485i. PMID 15634002.
  2. ^ Okun A, DeFelice M, Eyde N, Ren J, Mercado R, King T, Porreca F (January 2011). "Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents". Molecular Pain. 7: 1744-8069–7-4. doi:10.1186/1744-8069-7-4. PMC 3025866. PMID 21219650.
  3. ^ Shirazi M, Izadi M, Amin M, Rezvani ME, Roohbakhsh A, Shamsizadeh A (August 2014). "Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats". Neurological Sciences. 35 (8): 1235–41. doi:10.1007/s10072-014-1689-5. PMID 24577898. S2CID 24122557.
  4. ^ Amiresmaili S, Shamsizadeh A, Allahtavakoli M, Pourshanazari AA, Roohbakhsh A (February 2014). "The effect of intra-ventral hippocampus administration of TRPV1 agonist and antagonist on spatial learning and memory in male rats". Pharmacological Reports. 66 (1): 10–4. doi:10.1016/j.pharep.2013.06.002. PMID 24905300. S2CID 15631269.
  5. ^ Walters ET (August 2014). "Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense". Experimental Neurology. 258: 48–61. doi:10.1016/j.expneurol.2014.02.001. PMID 25017887. S2CID 39671969.
  6. ^ Bannazadeh M, Fatehi F, Fatemi I, Roohbakhsh A, Allahtavakoli M, Nasiri M, et al. (May 2017). "The role of transient receptor potential vanilloid type 1 in unimodal and multimodal object recognition task in rats". Pharmacological Reports. 69 (3): 526–531. doi:10.1016/j.pharep.2017.01.025. PMID 31994094. S2CID 210949267.
  • v
  • t
  • e
TRP channel modulators
TRPA
Activators
Blockers
TRPC
Activators
Blockers
TRPM
Activators
Blockers
TRPML
Activators
Blockers
TRPP
Activators
Blockers
TRPV
Activators
Blockers
See also: Receptor/signaling modulators • Ion channel modulators


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e